Company Introduces New Trade Name Onrigin(TM) for Laromustine
NEW HAVEN, Conn., Dec. 4 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today made several announcements related to events in connection with the 50th American Society of Hematology Annual Meeting at the Moscone Center in San Francisco from December 6-9, 2008.
Vion Poster Presentation
The Company announced that it would present survival data for its lead anticancer product laromustine in a poster presentation.
Title: "Survival After Complete Response to Treatment with Laromustine (Cloretazine(R)) in Elderly Patients with Poor Risk Acute Myelogenous Leukemia" Date: Saturday, December 6 Time: 9:30 a.m. to 7:30 p.m. (authors present 5:30-7:30 p.m.) Location: Moscone Center Hall A, Board I-45
New Trade Name for Laromustine
Vion will introduce Onrigin(TM) as the new trade name for laromustine at the Meeting, replacing Cloretazine(R) (VNP40101M).
Vion Co-Sponsors Seminar on Acute Myelogenous Leukemia in Elderly Patients
The Company is co-sponsoring a seminar at the Meeting, in conjunction with MGI Pharmaceuticals and the Geriatric Oncology Consortium, entitled "Treating AML/MDS in the Elderly: New Solutions for a Long-Standing Problem." The seminar will take place in Rooms 3009, 3011, 3022 and 3024 on Friday, December 5 from 12:30 p.m. to 4:30 p.m. at the Moscone Center West.
Other Posters Related to Laromustine and Triapine(R)
The Company announced that additional posters presented by investigators would be made on laromustine and Triapine(R), its second anticancer agent in
|SOURCE Vion Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved